Suppr超能文献

德国乙型、丙型和丁型肝炎的流行病学:范围综述。

The epidemiology of Hepatitis B, C and D in Germany: A scoping review.

机构信息

Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.

Department of Infectious Disease Epidemiology, Translational Infrastructure Epidemiology of the German Centre for Infection Research, Robert Koch Institute, Berlin, Germany.

出版信息

PLoS One. 2020 Mar 9;15(3):e0229166. doi: 10.1371/journal.pone.0229166. eCollection 2020.

Abstract

BACKGROUND

Germany is considered to be a low prevalence country for viral Hepatitis B, C and D (HBV, HCV, HDV). However, the burden of disease can be high among subpopulations. To meet the world Health Organization (WHO) viral hepatitis (VH) elimination goals, a national strategy was developed by the German government in 2016. We performed a scoping review to understand the baseline epidemiological situation in Germany regarding burden of disease, sequelae and care of HBV, HCV and HDV as a reference to monitor the progress of the national VH elimination and to identify further knowledge gaps and research needs.

METHODS

The protocol of the systematic review was prepared following the PRISMA statement guidelines for scoping reviews. Relevant search terms were used to identify eligible studies according to the research questions. We searched six online databases for original work published between January 2005 and March 2017. Based on the identified references, a matrix was developed presenting the eligible literature by targeted population group and outcome category.

RESULTS

104 publications were eligible for extraction covering 299 outcome results. The population groups targeted in the identified studies included the general population and proxy populations, a range of clinical populations, people who inject drugs, men who have sex with men, healthcare workers, people in prisons and different migrant/mobile populations. Other vulnerable populations (e.g. sex workers) were not targeted. Overall, good evidence was found for HBV and HCV prevalence and HBV vaccination coverage in the GP and proxy populations. Evidence for these outcomes was weaker in populations at risk for VH. For HBV and HCV incidence and mortality, we identified large evidence gaps in all population groups. Outcomes on VH sequelae and care were mainly covered by studies in clinical populations of people living with viral hepatitis. For HDV the overall evidence available was scarce.

CONCLUSIONS

We created a comprehensive evidence-based overview on the current epidemiological situation of viral hepatitis in Germany. We identified knowledge gaps for further research and established a baseline for future monitoring of viral hepatitis elimination goals in Germany.

摘要

背景

德国被认为是乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)和丁型肝炎病毒(HDV)流行率较低的国家。然而,在某些亚人群中,疾病负担可能很高。为了实现世界卫生组织(WHO)病毒性肝炎(VH)消除目标,德国政府于 2016 年制定了国家战略。我们进行了范围界定审查,以了解德国在 HBV、HCV 和 HDV 疾病负担、后遗症和治疗方面的基线流行病学情况,作为监测国家 VH 消除进展的参考,并确定进一步的知识差距和研究需求。

方法

根据系统评价的 PRISMA 声明指南制定了该系统评价的方案。根据研究问题使用相关搜索词来确定合格的研究。我们在 2005 年 1 月至 2017 年 3 月期间在六个在线数据库中搜索了原始作品。根据确定的参考文献,开发了一个矩阵,通过目标人群和结果类别展示合格文献。

结果

共有 104 篇出版物符合提取标准,涵盖了 299 项结果。所确定研究中的人群包括一般人群和代表性人群、一系列临床人群、注射毒品者、男男性行为者、卫生保健工作者、监狱中的人员和不同的移民/流动人口。其他弱势群体(例如性工作者)没有被定位。总体而言,在一般实践和代表性人群中,HBV 和 HCV 的流行率以及 HBV 疫苗接种覆盖率有很好的证据。在 VH 高危人群中,这些结果的证据较弱。对于 HBV 和 HCV 的发病率和死亡率,我们在所有人群中都发现了大量的证据差距。关于 VH 后遗症和治疗的结果主要由患有病毒性肝炎的临床人群的研究涵盖。对于 HDV,现有证据总体上很少。

结论

我们创建了一个关于德国病毒性肝炎当前流行病学情况的全面循证概述。我们确定了进一步研究的知识差距,并为德国未来监测 VH 消除目标奠定了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/332c/7062254/295298d0f396/pone.0229166.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验